DeepMed Research

Alliance for Clinical Trials in Oncology

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 2011-01-01

Employees: 251

Market Cap: -

Website: https://www.allianceforclinicaltrialsinoncology.org

Clinical Trials

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Phase 2

Recruiting

Conditions: Metastatic Malignant Neoplasm in the Brain
Metastatic Malignant Solid Neoplasm
PI3K Gene Mutation
KRAS G12C Mutation
NTRK Family Gene Mutation
CDK Gene Mutation
ROS1 Gene Mutation

Interventions: Drug: Entrectinib
Drug: PI3K Inhibitor paxalisib
Drug: Abemaciclib
Drug: Adagrasib

First Posted Date: 2019-06-21

Last Posted Date: 2025-04-02

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 186

Registration Number: NCT03994796

Locations: 🇺🇸
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Katmai Oncology Group, Anchorage, Alaska, United States

and more 433 locations

Avelumab with or Without Cetuximab in Treating Patients with Advanced Skin Squamous Cell Cancer

Phase 2

Active, not recruiting

Conditions: Skin Squamous Cell Carcinoma
Metastatic Skin Cancer

Interventions: Drug: Avelumab
Drug: Cetuximab

First Posted Date: 2019-05-10

Last Posted Date: 2025-02-18

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 60

Registration Number: NCT03944941

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States

and more 425 locations

Axillary Reverse Mapping in Preventing Lymphedema in Patients with Breast Cancer Undergoing Axillary Lymph Node Dissection

Phase 3

Active, not recruiting

Conditions: Breast Cancer Stage II
Breast Cancer Stage I
Breast Cancer Stage III

Interventions: Drug: Isosulfan Blue
Procedure: Axillary Lymph Node Dissection
Other: Quality-of-Life Assessment
Procedure: Mapping
Other: Questionnaire Administration

First Posted Date: 2019-04-25

Last Posted Date: 2025-01-17

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 534

Registration Number: NCT03927027

Locations: 🇺🇸
Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States

and more 93 locations

Assessment of Financial Difficulty in Participants with Chronic Lymphocytic Leukemia and Multiple Myeloma

Completed

Conditions: Chronic Lymphocytic Leukemia
Plasma Cell Myeloma

Interventions: Other: Medical Chart Review
Other: Interview
Other: Questionnaire
Other: Quality-of-Life Assessment

First Posted Date: 2019-03-12

Last Posted Date: 2025-01-17

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 521

Registration Number: NCT03870633

Locations: 🇺🇸
Heartland Regional Medical Center, Saint Joseph, Missouri, United States
🇺🇸
Sanford Bismarck Medical Center, Bismarck, North Dakota, United States
🇺🇸
Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States

and more 113 locations

Use of a Pre-Surgical Toolkit in Improving Surgical Care and Outcomes in Older Participants With Cancer

Not Applicable

Active, not recruiting

Conditions: Malignant Neoplasm
Carcinoma
Surgical Procedure, Unspecified
Health Care Provider

Interventions: Other: Informational Intervention
Other: Best Practice
Other: Questionnaire Administration
Other: Informational Intervention with Coaching

First Posted Date: 2019-02-28

Last Posted Date: 2025-02-21

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 325

Registration Number: NCT03857620

Locations: 🇺🇸
Mercy Medical Center - Des Moines, Des Moines, Iowa, United States
🇺🇸
Fairview Southdale Hospital, Edina, Minnesota, United States
🇺🇸
Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin, United States

and more 41 locations

Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer

Phase 3

Terminated

Conditions: Malignant Neoplasm

Interventions: Other: Placebo
Drug: Dexamethasone
Other: Questionnaire
Other: Quality-of-Life Assessment
Drug: Everolimus

First Posted Date: 2019-02-15

Last Posted Date: 2025-01-29

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 39

Registration Number: NCT03839940

Locations: 🇺🇸
Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States
🇺🇸
Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States
🇺🇸
Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States

and more 316 locations

Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making

Not Applicable

Active, not recruiting

Conditions: Breast Cancer Stage 0
Breast Cancer Stage II
Breast Cancer Stage III
Breast Cancer Stage I

Interventions: Other: Usual Care
Other: Web-based decision aid

First Posted Date: 2018-12-05

Last Posted Date: 2025-01-28

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 627

Registration Number: NCT03766009

Locations: 🇺🇸
Epic Care-Dublin, Dublin, California, United States
🇺🇸
Bay Area Breast Surgeons Inc, Emeryville, California, United States
🇺🇸
Contra Costa Regional Medical Center, Martinez, California, United States

and more 55 locations

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Phase 2

Conditions: Estrogen Receptor-positive Breast Cancer
HER2/Neu Negative
Stage IV Breast Cancer AJCC v6 and v7

Interventions: Drug: Palbociclib
Drug: Letrozole
Drug: Fulvestrant
Other: Questionnaire Administration
Other: Quality-of-Life Assessment

First Posted Date: 2018-08-16

Last Posted Date: 2021-10-15

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 93

Registration Number: NCT03633331

Locations: 🇺🇸
Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States
🇺🇸
Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States
🇺🇸
Kootenai Cancer Center, Post Falls, Idaho, United States

and more 443 locations

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

Phase 2

Recruiting

Conditions: Stage III Bladder Urothelial Carcinoma
Stage II Bladder Urothelial Carcinoma
Infiltrating Bladder Urothelial Carcinoma

Interventions: Drug: Gemcitabine Hydrochloride
Drug: Cisplatin
Biological: Pegfilgrastim
Procedure: Conventional Surgery
Procedure: Radical Cystectomy
Other: Chemoradiotherapy

First Posted Date: 2018-08-01

Last Posted Date: 2025-04-02

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 271

Registration Number: NCT03609216

Locations: 🇺🇸
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
🇺🇸
CTCA at Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸
Cancer Center at Saint Joseph's, Phoenix, Arizona, United States

and more 409 locations

Evaluation of Mammographic Breast Density in Participants with Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502

Terminated

Conditions: Breast Carcinoma
Estrogen Receptor Negative
Progesterone Receptor Negative

Interventions: Procedure: Screening Mammography
Procedure: Biospecimen Collection

First Posted Date: 2018-08-01

Last Posted Date: 2025-01-16

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 18

Registration Number: NCT03609021

Locations: 🇺🇸
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
🇺🇸
Virginia G Piper Cancer Care-Glendale, Glendale, Arizona, United States
🇺🇸
Kingman Regional Medical Center, Kingman, Arizona, United States

and more 510 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy